NeuroOne Medical (NMTC) Technologies accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company’s patented OneRF Technology Platform. The Company had previously projected a submission by the end of June 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMTC:
- NeuroOne’s Earnings Call: Record Growth and Positive Outlook
- NeuroOne Reports Strong Revenue Growth in Q1 2025
- NeuroOne Medical sees FY25 product revenue $8M-$10M vs. $3.5M last year
- NeuroOne Medical reports Q1 EPS 6c vs. (14c) last year
- NeuroOne Medical regains compliance with Nasdaq listing requirements